Skip to main content

Search

Clear
Filter by Type
Filter by Topics
Filter by Symptoms & Conditions
Filter by Year
Patient Specific Functional Scale (PSFS)

Oct 2, 2014/Test & Measure

Used to assess functional ability to complete specific activities.

Risk Assessment Prediction Tool (RAPT)

May 23, 2017/Test & Measure

Risk Assessment Prediction Tool (RAPT)

British Columbia Postconcussion Symptom Inventory (BC-PSI)

Jun 5, 2017/Test & Measure

This is a 16-item questionnaire, which includes 13 postconcussive syndrome symptoms (PCS) and 3 daily life problems.

Get to Know APTA Home Health: An Interview With Academy President Philip Goldsmith

Dec 10, 2024/Podcast

A brief introduction from the president of the academy.

New Study Reimagines the Relationship Between Daily Steps and Health Outcomes

Sep 3, 2025/Article

For decades, 10,000 steps a day has been regarded as a near-universal benchmark for fitness and general health goals — often promoted by wearable fitness trackers and public health campaigns. However, an August 2025 study, "Daily steps and health outcomes in adults: a systematic review and dose-response

Educational Leadership Conference Focuses on Creating a Sustainable Future

Aug 20, 2021/News

The Oct. 22-24 event is built around the importance of developing habits than can ensure a strong future for physical therapy education.

APTA Outstanding Research Award

Awards

This award encourages the publication of outstanding physical therapy research articles, including both foundational and clinical research impacting practice and patient care.

What Is PTPAC? Five Things You Need to Know

Feb 3, 2023/News

Our political action committee is working on issues that matter now and into the profession's future.

New Member Benefit a One-Stop-Shop for Prior Authorization, UM Advocacy Tools

Mar 15, 2022/News

APTA and the Private Practice Section have collaborated to create SPARC — the State Payer Advocacy Resource Center.

Rivermead Mobility Index for Multiple Sclerosis (MS)

Sep 12, 2013/Test & Measure

Target population: People with multiple sclerosis (MS).